← Leaderboards
Nader Sheibani
University Of Wisconsin Madison
$11,734,409
Attributed
$15,252,427
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$15,252,427 · 7
By mechanism
R24$6,155,825 · 1
R01$5,499,068 · 4
RC4$3,161,034 · 1
R03$436,500 · 1
Top collaborators
- Hao F Zhang6 shared
- Amir H Assadi1 shared
- Fariba M Assadi-Porter1 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Michael M Altaweel$4,628,844
- Deane Fremont Mosher$14,793,459
- Ronald Klein$10,952,330
- Michael John Schurr$2,411,971
Others in their field
Top investigators on “Angiogenesis”
- David Heimbrook · Leidos Biomedical Research, Inc.$75,067,502
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,567,306
- Martin Friedlander · Scripps Research Institute$48,350,175
- Larry Arthur$33,866,306
- Michael Simons · Yale University$30,647,106
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$29,372,588
Research focus
AngiogenesisRetinal DiseasesRetinalBlindnessBlood VesselsRetinaAffectOxygenPathogenesisPhenotypeNew GrowthProteinsInvestigationPhysiologicalNeovascularizationDiabetic RetinopathyGene ExpressionLeadImageCell AdhesionBaseEventAnimalsEffective Therapy
Grant awards (25)
Investigating oxygen metabolism in diabetic retinopathy$456,523
R01 · FY2020 · EY
Investigating oxygen metabolism in diabetic retinopathy$456,523
R01 · FY2019 · EY
Investigating oxygen metabolism in diabetic retinopathy$456,523
R01 · FY2018 · EY
Novel Antiangiogenic Peptides for Treatment of Exudative AMD$1,213,468
R24 · FY2017 · EY · contact PI
Investigating oxygen metabolism in diabetic retinopathy$456,523
R01 · FY2017 · EY
Novel Antiangiogenic Peptides for Treatment of Exudative AMD$1,320,393
R24 · FY2016 · EY · contact PI
Investigating oxygen metabolism in diabetic retinopathy$468,394
R01 · FY2016 · EY
Novel Antiangiogenic Peptides for Treatment of Exudative AMD$1,148,492
R24 · FY2015 · EY · contact PI
Novel Antiangiogenic Peptides for Treatment of Exudative AMD$1,230,010
R24 · FY2014 · EY · contact PI
Novel Antiangiogenic Peptides for Treatment of Exudative AMD$1,243,462
R24 · FY2013 · EY · contact PI
PECAM-1 and Retinopathy of Prematurity$307,912
R01 · FY2011 · EY · contact PI
Integrated Multidisciplinary Strategies for Detection of Diabetic Retinopathies$3,161,034
RC4 · FY2010 · EY · contact PI
CYP1B1 and Retinopathy of Prematurity$362,521
R01 · FY2010 · EY · contact PI
PECAM-1 and Retinopathy of Prematurity$320,742
R01 · FY2010 · EY · contact PI
CYP1B1 and Retinopathy of Prematurity$350,550
R01 · FY2009 · EY · contact PI
PECAM-1 and Retinopathy of Prematurity$323,982
R01 · FY2009 · EY · contact PI
PECAM-1 and Retinopathy of Prematurity$317,502
R01 · FY2008 · EY · contact PI
PECAM-1 and Retinopathy of Prematurity$323,982
R01 · FY2007 · EY · contact PI
Thrombospondin-1 and retininal vascular homeostasis$145,500
R03 · FY2005 · EY
Thrombospondin-1 and retininal vascular homeostasis$145,500
R03 · FY2004 · EY
PECAM-1 AND REGULATION OF ANGIOGENESIS$230,286
R01 · FY2003 · AR
Thrombospondin-1 and retininal vascular homeostasis$145,500
R03 · FY2003 · EY
PECAM-1 AND REGULATION OF ANGIOGENESIS$224,325
R01 · FY2002 · AR
PECAM-1 AND REGULATION OF ANGIOGENESIS$218,524
R01 · FY2001 · AR
PECAM1 AND REGULATION OF ANGIOGENESIS$224,256
R01 · FY2000 · AR